122 related articles for article (PubMed ID: 26215963)
1. Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
Negri FV; Porta C
J Clin Oncol; 2015 Oct; 33(28):3219-20. PubMed ID: 26215963
[No Abstract] [Full Text] [Related]
2. Reply to F.V. Negri et al.
Ye SL
J Clin Oncol; 2015 Oct; 33(28):3220-1. PubMed ID: 26215937
[No Abstract] [Full Text] [Related]
3. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
4. Painful Rashes on the Palms and Soles.
Bhullar M; Bhullar A; Arachchi NJ
Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
[No Abstract] [Full Text] [Related]
5. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Lien RY; Tung HH; Wu SL; Hu SH; Lu LC; Lu SF
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1532. PubMed ID: 34910380
[TBL] [Abstract][Full Text] [Related]
6. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
7. [Effective Prevention of Hand-Foot Syndrome by the Consumption of Dried Bonito Broth].
Kamimura K; Shinagawa Y; Ogawa K; Kobayashi Y; Abe H; Yokoo T; Kamimura H; Kawai H; Suda T; Yamagiwa S; Baba H; Terai S
Gan To Kagaku Ryoho; 2016 Apr; 43(4):463-5. PubMed ID: 27220795
[TBL] [Abstract][Full Text] [Related]
8. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Wang P; Tan G; Zhu M; Li W; Zhai B; Sun X
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):1-8. PubMed ID: 28847184
[TBL] [Abstract][Full Text] [Related]
9. [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Chen X; Jiang Y; Zhang Y; Dai W; Fan R; Weng X; He P; Yan F; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1488-1492. PubMed ID: 33118519
[TBL] [Abstract][Full Text] [Related]
10. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
11. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
[No Abstract] [Full Text] [Related]
12. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
13. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
14. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
[No Abstract] [Full Text] [Related]
15. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
Tajiri K; Nakajima T; Kawai K; Minemura M; Sugiyama T
Intern Med; 2015; 54(6):597-600. PubMed ID: 25786448
[TBL] [Abstract][Full Text] [Related]
16. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
17. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
18. Severe adverse skin reaction and desensitization to sorafenib.
Linauskiene K; Malinauskiene L; Vitkauskaite E; Chomiciene A; Blaziene A
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):209-10. PubMed ID: 27372655
[No Abstract] [Full Text] [Related]
19. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
[No Abstract] [Full Text] [Related]
20. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
